AREDIA
LOE ApproachingNDAINJECTIONINJECTABLE
Approved
Sep 1998
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 2h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
AREDIA (pamidronate disodium) is an intravenous bisphosphonate approved in 1998 for treating hypercalcemia of malignancy and osteolytic bone metastases in breast cancer and multiple myeloma. It works by inhibiting osteoclast-mediated bone resorption, reducing serum calcium and slowing bone destruction in cancer patients.
LOE Approaching
Mature product in late lifecycle with moderate competitive pressure (30/100), indicating consolidated team size and focus on market defense rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
AREDIA offers limited career growth opportunities given its LOE-approaching lifecycle and zero linked job postings, indicating a contracted commercial team focused on revenue protection rather than expansion. Roles available are typically in sales, account management, and defensive market strategy rather than innovation or launch-phase activities.
Brand ManagerField Sales Representative
Worked on AREDIA at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.